Status: Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: C. Babis AndreadisUpdated: Jun 22, 2026Locations: 1
Eligibility criteria
Participants must have a diagnosis of relapsed or refractory Burkitt Lymphoma [+19]
Autologous transplant within 6 weeks of planned CAR-T cell infusion. [+14]